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of an iinpact of ivermectin on OND in follow-up periods of
1-3 years, but those studies had much smaller sample sizes
than our trial.
We must be cautious in extrapolating our findings to
other onchocercal communities. The likely unpact of
ivermectin on OND (all causes) will depend on the
Proportion of OND in those communities that is due to
onchocerciasis. DEC was widely used in the area where our
trial took place, and though we found no evidence that the
rate ratio for ivermectin versus placebo varied with previous
consumption of DEC, we have no reliable, systemaoc data
on the consumption of DEC during the trial; the effect of
ivermectin on OND due to onchocerciasis may vary with the
extent of continuing DEC consumption.
Unpubhshed data from our trial suggest that OND is an
important pathway to blindness due to guinea savannah
onchocerciasis. Regulär treatment with ivermectin may
substantially reduce the risk of onchocercal blindness
among individuals living in the guinea savannah with
microfilarial loads above 10 mf/mg.
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Increased risk of venous thrombosis in carriers
of hereditary protein C def iciency defect
C. F. ALLAART SWIBERTUS R. POORT FRITS R. ROSENDAAL
PIETER H. REITSMA ROGIER M. BERTINA ERNEST BRIET
The relevance of heterozygosity for hereditary
protein C deficiency äs a risk factor for venous
thrombosis has been disputed because
heterozygotes without Symptoms have been
identified among blood donors and relatives of
homozygotes. As a result, clinicians do not know
whether to offer prophylaxis or not. We have
compared thrombosis-free survival in 161
heterozygous and normal members of the families
of 24 heterozygotes for protein C deficiency referred
from several centres in the Netherlands and with a
history of Symptoms. We studied the influence of
heterozygosity and of putative additional risk
factors on the occurrence of thrombotic events
noted when a medical history was taken. Protein C
activities were measured but a diagnosis of
heterozygosity was based on the presence of the
specific mutation m one of the protein C genes
identified in the proband of the family.
We found a significant difference in the
thrombosis-free survival of the 77 heterozygotes
and 84 normals. by age 45, 50% of heterozygotes
and 10% of normal relatives can be expected to have
had a manifestation of venous thromboembohsm.
The presence of such a mutation was clearly
associated with an increased risk of venous
thrombotic events. Thrombotic events occurred
more often in years m which the patient had been
immobile for more than a week or had had surgery.
Other putative risk factors showed no significant
effect in the incidence of thrombotic events. About
50% of all first episodes and 65% of recurrences of
venous thromboembolism in the heterozygotes
were spontaneous—ie, there was no predisposing
event such äs surgery or pregnancy. There was no
increased risk for artenal occlusions in heterozygotes.
We conclude that members of the family of a
symptomatic heterozygote proband who are
heterozygous for the mutation in the protein C gene
have an increased risk of venous thrombotic events
compared with their normal family members. For
such individuals prophylactic anticoagulation
should be considered; the decision will need to be
taken on an individual basis.
Lancet 1993, 341:13Φ-38
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Introduction
Protein C is a vitamin-K-dependent glycoprotein that is
the zymogen of one of the main Inhibitors of the coagulation
System.1 After activation by the thrombin-thrombomodulin
complex, activated protein C inactivates factors Va and
Villa23 in the presence of protein S, calcium ions, and
phospholipids.4 Since protein C has anticoagulant
properties it is not surprising that heterozygosity for
hereditary protein C deficiency has been associated with a
tendency to venous thrombosis.6-10 In 1983 the first patient
with homozygous protein C deficiency was reported.11
Surprisingly, his heterozygous family members were not
thrombosis prone, and subsequent reports confirmed this in
other families.12-15 In 1987 Miletich et al identified 79
heterozygotes for protein C deficiency among 5422 healthy
blood donors. None had experienced a thrombotic event. In
4 of them the hereditary nature of the deficiency was
confirmed.16 In the light of these findings, a role for
heterozygous protein C deficiency äs a risk factor in venous
thrombosis has been disputed.
Clinicians want to know if prophylactic measures are
advisable for patients with protein C deficiency and their
relatives. Before this question can be answered the risk for
thrombosis in these individuals needs to be assessed. We
have studied 24 families with hereditary protein C
deficiency in which at least one person had had thrombosis.
The diagnosis of the deficiency was based on the presence or
absence of specific point mutations in protein C genes. We
then calculated the thrombosis-free survival of the
heterozygotes and the genetically normal relatives.
Patients and methods
Patients and families
The study was approved by the University Hospital, Leiden
medical ethics committee and informed consent was obtained from
all parricipants. When the study began 80 Dutch probands with
venous thrombosis and protein C deficiency were known to this
centre. The diagnosis was based on the repeated finding of protein
C antigen levels below 0-65 U/ml for patients not on oral
anticoagulants or below 0-33 U/ml for those on stable coumarin
therapy.6 From these 80 probands, 25 were randomly selected for
DNA analysis. In 24 probands a point mutation was identified in
one protein C gene (table i).17 All siblings and children (over 16
years of age) and parents of the proband plus siblings of the defitient
parent were invited to take part in the study. Of the 175 eligible
individuals 161 (92%)didtakepart;7non-participantslivedabroad
and 7 others did not take part because of poor health (3) or for
reasons unknown (4). 18 family members who would have been
eligible had died before the study began. 6 of these 18 were reported
to have had thrombosis, and pedigrees suggested that 3 of these 6
were obligatory heterozygotes for the deficiency. The genotype of
the others is unknown. 64 of the 161 participating family members
had already been tested for protein C deficiency and abnormally low
antigen levels had been found in 35. They knew this earlier result
but we did not. DNA analysis had not been done previously.
All 161 participants were interviewed by one physician (C. F. A.),
who took a medical history with emphasis on manifestations of deep
venous thrombosis (DVT), pulmonary embolism, and superficial
thrombophlebitis. Age at each such manifestation was noted,
together with possible predisposing circumstances, method of
diagnosis, and treatment. Participants were also asked about
Potential risk factors for the venous thrombosis—ie, surgery,
immobilisation, pregnancy and childbirth, cardiac and liver disease,
malignancy, varicosities, smoking, and oral contraceptives—and
questions were asked with respect to the manifestation of arterial
occlusive disease.
Laboratory methods
Blood samples were collected from the antecubital vein in 1/10
volumeofO-11 mmol/L trisodium citrate. Plasma was prepared by
TABLE l—MUTATIONS FOUND IN 24 FAMILIES WITH
HEREDITARY PROTEIN C DEFICIENCY TYPE l
Mutation
2»Arg-»Cys
132Gln-»stop
76Phe-»Leu
'«Arg-vstop
JOSCys-*Tyr
178Arg->Trp
"
3IIe-.Met
2S6Asn->Asp
M2Gly-»Ser
3222 G->T
Exon
9
6
5
9
6
7
9
9
9
5t
Noof
families
7*
5
9
2t
2
1
1
1
1
1
No of heterozygotes
(participants)
16(37)
10(35)
10 (21)
10 (18)
10 (17)
3(10)
7(8)
4(6)
4(5)
3(4)
*Two families related through common ancestors in 1820.
tRetated through common ancestors m 1880.
tDonor splice site 3' side of exon 5.
centrifugation for 10 min at 2000 g at 10°C and stored at — 70°C.
High-molecular-weight DNA was isolated from leucocytes and
stored at 4°C.
Protein C activity was measured with Coatest (Kabi Diagnostica,
Stockholm) on an ACL 300 (Instrumentation Laboratories,
Milan). Pooled normal plasma from 67 healthy volunteers served äs
a reference. Protein C activity is expressed in U/mL, where l U
refers to the activity in l mL pooled normal plasma.
We used polymerase chain amplification (PCR)18 to detect
alterations in the coding sequence of the protein C gene in the
probands. In family members mutations were identified äs altered
digestion patern for particular restriction enzymes or by direct
sequencing.17 The Identification of heterozygotes and normale was
done by two molecular biologists (S. R. P., P. H. R) who did not
know the protein C measurements or the medical history.
Statistics
Laboratory data are expressed äs mean (SD) with comparisons
by Student t test. We constructed thrombosis-free survival curves
by the Kaplan and Meier method,19 comparing them by a logrank
test (chi-square distribution, one degree of freedom). Confidence
intervals (CI) for the thrombosis-free survival rates were calculated
on a binomial distribution.
The incidence of first thrombotic events in heterozygotes and
normals was calculated by counting patient-years of observation
and dividing the number of events in each group by the sum of
observation-years of all the individuals in the group. Similarly,
incidence rate ratios for surgery and immobilisation were calculated
äs the ratio of the incidence of thrombosis in the years that surgery
(or immobilisation) took place and the incidence rate in all other
years. CI for incidence or incidence rate ratios were calculated on a
Poisson distribution.20
We calculated crude (univariate) odds ratios äs an approximation
of relative risk for several putative risk factors by simple cross-
tabulation. These odds ratios reflect the risk when the proposed risk
factor is present relative to the risk when it is absent, unadjusted for
other factors. We then used a Cox proportional hazards model in a
multivariate survival analysis allowing several factors to be adjusted
for simultaneously. The hazard ratio is the incidence rate ratio,
which is assumed to be constant over time, whereas the baseline
hazard is allowed to vary.21 This hazard ratio may be interpreted äs
the relative risk associated with each factor, adjusted for all other
factors in the model.
Results
Laboratory results
In the twenty-four families ten different mutations were
identified, five in more than one family (table l). Extensive
genealogical studies proved a common ancestry in the two
306Arg -> stop families and in two of the 230Arg->Cys
families17 but no such connections were found in the other
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families. Of the 161 participants, 77 were heterozygous for
protein C deficiency (33 men, 44 women; average age 47-2
years, ränge 18-83), on the basis of mutations in the protein
C gene. 84 were normal (38 men, 46 women; average age
45-3 years, ränge 16-82).
In every family low protein C activity levels co-segregated
with the mutation — ie, both had been transmitted together
through the generations. However, not all heterozygotes had
a low protein C activity, and there was a large overlap in
protein C activities measured in 60 heterozygotes and 83
normals not on anticoagulant therapy (fig 1). Fitting a
gaussian curve to the frequency distributions suggested that
15% of heterozygotes would not be identified and 5% of
normals would be labelled deficient if the diagnosis were to
be based on protein C activity only, with the lower limit of
normal of 0·65 U/mL. Heterozygotes not on oral
anticoagulant therapy and with no Symptoms had slightly
higher protein C activities (56-0 [13-7] U/mL) than
heterozygotes with Symptoms (50-8 [13-0] U/mL), but this
difference was not significant.
Clinical data
Of the 77 heterozygous relatives of the probands 35 (45%)
had experienced one or more venous thrombotic events; 16
had previously been diagnosed äs deficient but the other 19
were newly diagnosed heterozygotes. Of 7 heterozygotes
previously labelled normal on the basis of protein C antigen
levels, l reported having had a thrombotic event.
First Symptoms were D VT in a leg in 21 heterozygotes
and pulmonary embolism in 10. Diagnosis and
anticoagulant treatment were based on clinical presentation
only in 21 of these 31 events. 4 heterozygotes had superficial
thrombophlebitis äs a first manifestation and 8 had a
combination of deep and superficial thrombosis. The first
episode was spontaneous in 17 patients (49%); in 8 the
episode followed surgery or trauma, in 7 childbirth (2
caesarean sections), in 2 during pregnancy, and in l during a
period of immobilisation exceeding l week. More than one
event had occurred in 18 of the 35 heterozygotes with
Symptoms. 22 of the 34 recurrences were spontaneous
(65%); the others were associated with trauma or surgery
(4), immobilisation (2), pregnancy (4), and childbirth (2).
40 50
Age (yr)
Fig 2—Venous-thrombosis-free survival curves in
heterozygotes and normal relatives.
Probability of freedom from venous thrombotic events presented in
Kaplan-Meier analysis for 77 heterozygotes and 84 normal relatives.
Difference in curves significant (χ2=25 3; p<0 0005) Steps in curves
indicate events; short vertical lines indicate losses to the analysis because
of age of survivor
7 of the 84 normal relatives, in five different families, had
manifestations of venous thromboembolism: 3 had D VT in
a leg, 2 had pulmonary embolism, and 2 had superficial
thrombophlebitis. In 3 of the 5 deep thrombotic events
diagnosis and anticoagulant treatment had been based on
the clinical presentation only. The first episode was
spontaneous in 3, after surgery in l, childbirth in 2, and
prolonged immobilisation during pregnancy in 1. 3 normal
relatives had recurrences and of the 13 recurrences 4 were
spontaneous and l followed surgery and 8 were after
childbirth.
The thrombosis-free-survival curves (fig 2) show that at
the age of 45 the probability that a heterozygote will be free
of venous thrombosis is 0-5 (95% CI 0-31-0-71) while for
normal relatives it is 0-9 (95% CI 0-8-1 -0). The incidence of
first thrombotic events in heterozygotes was 4-1 per 1000
person-years up to age 25 (vs 0-5 per 1000 in normal
relatives); between 26 and 45 years it was 17-0 per 1000
person-years (vs 4-3), and between 46 and 83 years it was
12-9 per 1000 person-years (vs 1-7).
The difference in thrombosis-free survival in fig 2 cannot
be attributed to differrring frequencies of potential risk
factors for thrombosis (table n). The risk of venous
thrombosis was strongly influenced by the presence of a
mutation in one of the protein C genes (hazard ratio 8-8,
95% CI 3-6-21-5) (table Hl). The incidence of thrombotic
events was greater in the years in which the participants had
had an Operation (88 per 1000 person-years, compared with
10 per 1000 in years with no surgery; incidence ratio 9-2
[95% CI 5-0-16-8]). It was also greater in years in which
they had been immobilised for more than a week (82 per
1000 person-year compared with 11 per 1000 person-years
TABLE II—POTENTIAL RISK FACTORS IN 77 HETEROZYGOTES
AND 84 NORMAL RELATIVES
Potential nskfactor
Female sex
Surgery/trauma
Immobilisation
Pregnancy and childbirth
Oral contraceptive use*
Smoking*
Overweight by > 10 kg
Varicosities
Malignancy*
No of individuals (no of episodes) in:
Heterozygotes
44
54 (120)
35 (52)
34(87)
24
36
7
18
0
Normal relatives
46
62 (127)
33 (55)
32(119)
27
47
10
15
1
*Mentioned is number of tndividuals in whom nsk factor was "ever" present
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TABLE III—EFFECT OF POTENTIAL RISK FACTORS ON THE
OCCURRENCE OF VENOUS THROMBOTIC EVENTS IN ALL 161
PARTICIPANTS
Potential risk factor
Heterozygosity
Femalesex
Surgery/traumat
Immobilisationt
Pregnancy and
childbirtht
Oral contraceprive
uset
Smokingt
Overweight > 10 kg
Varicosity
Malignancyt
Venous thrombotic
event (yes/no) in:
Exposed
35/42
28/62
34/82
21/47
24/42
15/36
20/63
6/11
15/18
0/1
Non-
exposed
7/77
14/57
S/37
21/72
18/77
27/83
22/56
36/108
27/101
42/118
Crude
OR
9-2
1-8
1-9
1-5
2-4
1-3
0-8
1-6
3-1
0
Hazard
ratio*(95%CI)
8-8 (3-6-21-5)
1-7(0-4-5-9)
1-9 (0-8-4-6)
1-2(0-7-2-3)
0-9 (0-3-2-9)
1-3 (0-5-3-2)
1-2 (0-6-2-4)
1-7(0-6-4-5)
1-5(0-7-3-3)
2-7 (0-3-27-9)
*Proportional hazards model; all listed proposed risk factors entered.
f'Ever" had risk factor compared with "never".
in years without immobilisation; incidence rate ratio 7-6
[95% CI 3-7-15-7]). An association between a history of
surgery or immobilisation and an increased risk of venous
thrombotic events was also found in crude odds ratios and in
the proportional hazards model. In the proportional hazards
model overweight, female sex, a history of malignancy, and,
to a lesser extend, varicosities and a history of oral
contraceptive use or cigarette smoking, all appeared to be
associated with an increased risk, but for none of diese
factors was this eifert significant (table in).
7 heterozygotes had experienced manifestations of arterial
ocdusion: l had angina pertoris at age 69; 2 had a myocardial
infarction at age 50 and 67, l had intermittent claudication at
45; l had a stroke at 73; 2 had a transient ischaemic attack at
48 and 72. 5 normal relatives had experienced
manifestations of arterial occlusion: l had angina pectoris at
age 60; l had a myocardial infarction at 60; l had
intermittent claudication at 78; and 2 had a transient
ischaemic attack at 18 and 50. 35 heterozygotes and 29
normals were over 50. These limited data do not suggest that
a heterozygous state for protein C deficiency is associated
with an increased risk of arterial occlusion.
Discussion
Eleven years after the fürst report on hereditary protein C
deficiency, the importance of this äs a risk factor for venous
thrombotic events is still uncertain. In many family reports
an association between a thrombotic tendency and protein C
deficiency has been established, and in groups of selerted
patients with venous thrombotic disease the frequency of
protein C deficiency was 3-8 % .22J4 It was estimated, from a
study in 319 patients treated with oral anticoagulants for
venous thrombosis, that the prevalence of hereditary protein
C deficiency in the population is l in 16 OOO.25 However, the
Identification of symptom-free heterozygotes in a large
group of healthy volunteers put the prevalence at between l
in 200 and l in 300.16
In our study the participants, being aware of a thrombotic
tendency in their families, may have overstated the history of
thrombotic events. Overstatement is all the more likely
because many of the events had been diagnosed and treated
on the basis of clinical presentation only. However, 40 of the
42 first thrombotic events predated the diagnosis of protein
C deficiency in the family and the participants did not at the
time of interview know whether they carried the defect or
not. Any bias, in patients or physicians, will be the same for
heterozygotes and for normals.
The heterozygous relatives (parents, siblings, children,
aunts, and uncles) of our symptomatic patients with protein
C deficiency were at increased risk of a venous thrombotic
event. Identification ofthose at risk is therefore worthwhile.
This may be difficult if the diagnosis depends on protein C
activity alone because of the overlap between plasma
heterozygotes and normals (fig 1). In our study, 13 of the 77
heterozygotes identified by DNA analysis had protein C
activity levels that lay within the normal ränge for our
laboratory, and 2 of the 84 normal relatives had a protein C
activity just below that ränge. It is not clear whether the risk
of venous thrombosis is related to the level of protein-C
activity. There was no difference in activity levels in
asymptomatic heterozygotes and in heterozygotes who had
had a thrombotic event in the past. Shortly after
participating in our study l man was admitted to hospital
with spontaneous pulmonary embolism. His protein C
activity 2 weeks earlier had been normal (76%). He proved
to be heterozygous for the 230Arg-»Cys mutation present in
his family.
The difference in thrombosis-free survival between the
heterozygotes and the normal relatives cannot be explained
by a difference in potential risk factors for thrombosis.
When several such factors were taken into account at the
same time it was the presence of a protein C gene mutation
that emerged clearly äs carrying the highest risk for a venous
thrombotic event (table III). Being female or overweight or
having a history of malignancy, varicosity, smoking, or the
use of oral contraceptives seemed to be associated with some
increase in risks but individually these were not significant.
In the heterozygotes 9% of all episodes of trauma, surgery,
immobilisation and childbirth were complicated by a
thrombotic event. In normal relatives this proportion was
4d/o. These thrombotic complications accounted for 50% or
so of all first manifestations and 50% of recurrences. All
other thrombotic episodes were "spontaneous".
In a family with hereditary protein C deficiency in which
at least one person has had a thrombotic event, prophylaxis
must be considered for heterozygotes whether or not they
have Symptoms. However, the benefits and risks of
anticoagulant therapy are difficult to establish in general
terms so any advice will have to be given individually.
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Frequency of clonal remission in acute myeloid
leukaemia
ROSEMARY E. GALE HELEN WHEADON ANTHONY H. GOLDSTONE
ALAN K. BURNETT DAVID C. LINCH
Analysis of X-chromosome inactivation patterns in
females has been used to assess clonality of vanous
tumours and for prenatal diagnosis of X-hnked
disorders. Studies with these methods in acute
myeloid leukaemia suggest that a significant
Proportion of cases have clonal remissions (ie,
persistence of the malignant clone), which may
represent return to a preleukaemic state. We theref ore
analysed X-chromosome inactivation patterns with
differential methylation patterns of heterozygotes for
three DNA probes, HPRT, PGK, and M27ß, m
leukaemic patients and normal controls.
As expected, blast cells from 67 of 68 analysable
samples (99%) were monoclonal or had a skewed
X-inactivation pattern. A skewed pattern in remission
was also found in 26 of 77 patients (34%),
Proportion only slightly greaterthan control (16/75,
21%). In 7 of 10 patients with a skewed pattern in
myeloid cells there was similar skewing in the T cells,
which is compatible with the concept of a
constitutively skewed X-chromosome inactivation
pattern of haemopoietic cells in these patients.
Our study illustrates the difficulty of interpreting
clonality in individual tumour samples and
emphasises the importance of comparisons with
non-malignant tissue of the same cell type from that
individual and from normal control populations.
Lancet 1993, 341:138-42
Introduction
Clinical remission in acute myeloid leukaemia (AML) is
the restoration of a normal peripheral blood count with less
than 5% blast cells in the bone marrow,1 which is generally
thought to represent the return of normal polyclonal
haemopoiesis. However, Powles et al2 raised the possibility
that many cases of remission could be due to differentiation
of residual leukaemic cells after chemotherapy, and use of
X-linked techniques has shown apparent clonality or
ohgoclonality of remission granulocytes.3"5 This observation
might represent persistence of the leukaemic clone at an
earlier stage in its evolution, when a growth advantage over
normal cells is present but cell growth is soll regulated and
füll differentiation occurs.
In females, clonality can be studied by analysing X-
chromosome inactivation patterns with techniques that
distinguish between alleles on the two X chromosomes. The
inactivation of one of the X chromosomes in each cell at an
early stage in embryogenesis is a random process called
Lyonisation.6 A population of normal cells will therefore
contain a mixture of the two alleles in the ratio in which they
are actively expressed. A clone of tumour cells expresses only
a single allele, äs inherited from the original aberrant cell.
The first studies used isoenzymes of glucose-6-phosphate
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